Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial
Version 2 2024-06-03, 02:25Version 2 2024-06-03, 02:25
Version 1 2024-01-05, 05:03Version 1 2024-01-05, 05:03
journal contribution
posted on 2024-01-05, 05:03authored byM Alexander, Ian CollinsIan Collins, P Abraham, C Underhill, S Harris, J Torres, S Sharma, B Solomon, A Tran-Duy, K Burbury
This cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist centre. The Australian phase 3 cancer interventional randomised controlled trial included 152 of 328 regional participants (patient enrolment 2018–2021; 6-month primary end point). The NTTM significantly reduced (AU$2155 per patient) patient travel cost and time and lost productivity.